Raj holds a BA from Cornell University, where he majored in Chemistry. Sarah began her legal career with Foley, Hoag, & Eliot LLP. James McArthur is an Advisor for RA Capital Management. He holds a BA from Cornell University and a PhD in Virology from Harvard University. Prior to CVS Health, Prithviraj was a Senior Research Associate at the Gerson Lehrman Group. Ramaswamy, who just turned 30, has bigger aspirations. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. In his Venture role, Mario is focusing on early-stage investment and company creation. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. Anthony Arceci is a Senior Associate with the TechAtlas division of RA Capital Management. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. While at Orbimed, he drove proprietary deal sourcing, diligence, negotiation, and investment decisions for growth stage companies and determined valuation ranges for companies and products with a focus on technology platform value, commercial potential, and binary catalysts such as clinical and regulatory milestones. Adam Rosenberg is an Advisor for RA Capital Management. Medicare 'negotiating' drug prices will hurt Americans, not help - STAT Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. in Business Administration in Management Information Systems from Northeastern University. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. He works closely with RA's Investment Team on novel drug discovery platforms with emphasis on computational chemistry and machine learning. Mariagrace previously worked as an Executive Assistant at MPM Capital. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. in Biomedical Anthropology from the University of Pennsylvania. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. Steve's survey is fascinating. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. Peter Kolchinsky Founder and CEO RA Capital Management. Dans primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Prior to BHP, Brigid was at In-Q-Tel (IQT), the strategic investment arm of the CIA and the US Intelligence Community; she co-founded IQT's Australian subsidiary, served as its Managing Director, and built an international program to support a global innovation initiative through investing in the Asian-Pacific region. She is a CPA. Peter Kolchinsky, Ph.D. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. Asthas primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. She earned an MBA with focus in entrepreneurship & strategic management from AB Freeman School of Business at Tulane University and her MD from Tulane School of Medicine. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. No Patient Left Behind | Steering committee | Peter Kolchinsky Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. Toms primary responsibility is to support all aspects of trade and treasury operations. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Prior to RA Capital, Tyler worked as a freelance graphic designer. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. Emily Gransky is VP of Recruiting at RA Ventures (RAVen). Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. He worked previously as a Patient Coordinator at Massachusetts General Hospital. Pieter holds a BA from Trinity College and a JD from Yale Law School. Monicas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . Angela previously held roles as Senior Director of Clinical Operations and Patient Advocacy at Vigil Neuroscience and at Ra Pharmaceuticals. The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Hearing the stories of how patients couldn't afford the . Jenna previously held roles as Senior Medical Writer and Analyst at Costello Medical Consulting. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Dan Guglielmo is IT Operations Associate at RA Capital Management. Kathryn Spencer is an Executive Assistant at RA Capital Management. Phi Thach is an Executive Assistant at RA Capital Management. Emily Greenis a Visual Identity Designer at RA Capital Management. Christina is a Senior Science Writer at RA Capital Management. Lucas previously held Law Clerk positions at The Community Builders, Inc. and at Nixon Peabody LLP. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Peter's age is in line with some of the older Vanderpump Rules cast members, like Jax, Tom Sandoval, and Tom Schwartz. Mark brings to RAVen more than twenty-five years of leadership experience in the life sciences industryspanning operations, corporate development, legal affairs, and intellectual property. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. EMEA +44 20 7330 7500. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Currently, Dr. Kolchinsky occupies the position of Chairman & Chief Executive Officer of Research Alliance Corp. II (which he founded in 2020) and Managing Partner at RA Capital Management LP (which he founded in 2004), Managing Partner at RA Capital Management LP (Private Equity) (which he founded) (a subsidiary of RA Capital Management LP). Prior to Akebia, she gained Administrative and Resource Management experience at Wellington Management and Signature Consultants, respectively. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. Peter Pan & Wendy supports the theory that Peter Pan is the real villain of his respective franchise with its depiction of the beloved Disney character. RA Capital | Team Bethany is a Senior Finance Associate at RA Capital Management. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Christinas previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Joshs primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Michael's previous experience includes venture development at Health Wildcatters Seed Accelerator and product development in various roles at the Institute for Environmental and Exercise Medicine and as an Aerospace Medicine Clerk at NASA. Analysis: Top Biotech VC Investors in 2021 Based on - Insider James is admitted to practice law in the Commonwealth of Massachusetts. Prior to RA, Megan worked as a Gastroenterology Fellow at University of Pittsburgh Medical Center and a Resident Physician, Internal Medicine, at Beth Israel Deaconess Medical Center. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. in Business Administration in Management with a Minor in Biology from UMass Amherst Commonwealth Honors College. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. Cristina has nearly a decade of experience in the biotech and life sciences industries. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Most recently, Tom served as Director of Operations at TPRV Capital, LP. Peter Kolchinsky - Managing Partner - CrunchBase Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. Brendan holds a MS in Accounting with a concentration in Taxation from Merrimack College and a BA in Economics from University of Massachusetts Amherst. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. Dan studied Network Communications & Information Services at Lincoln Technical. FORBES estimates that Roivant is worth $3.5 billion, making its Millennial founder's 20% or so stake worth some $700 million. Bio Peter Kolchinsky Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation. She also has a Master's in Accounting from Boston College and is a CPA. Find Peter Kolchinsky's contact information, phone numbers, home addresses, age, background check, white pages, resumes and CV, places of employment, social media profiles, photos and videos, public records, arrest records, work history, news and business records . and Novus Biologicals. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. Chris Caliri is the Chief Information Officer at RA Capital Management. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. She has published over fifty papers in peer reviewed journals. Henry Stusnick is an Associate at RA Capital Management. Previously, Derek covered solid tumor oncology landscapes. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. Future In Sight with Peter Kolchinsky - FoodAllergy.org Kathryn holds a BA in Geography and Peace and Conflict Studies from Colgate University, a MSc in International Development: Environment and Development from the University of Manchester (UK), and a MA and Ph.D. in Geography from Clark University (2016). Timothy is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. Daphne Zohar is the founder and CEO of PureTech. Cosmass academic research has been published in journals such as Cell, Science, and Nature. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Brendans primary responsibility is managing all aspects of the tax function. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Alonso completed his Ph.D. in Chemistry at the University of Florida and his post-doctoral work as a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. Most recently, Brian served as Analyst, Biotech/Pharma/Specialty Pharma at Tamarack Capital Management. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Cony D'Cruz is a Venture Partner at RA Ventures. Before joining Rubius, Mark spent a decade launching, building or advising a portfolio of early-stage venture backed life-sciences companies, including Visterra, Living proof, Kala Pharmaceuticals, and Homology Medicines. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generation Bio, leading hiring across all functions and building out systems to support that growth. Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Mario is a Venture Partner and Head of Vaccines at RA Capital. I would love to talk to the 1 out of 7 VCs who thinks non-orphan small molecules for older patients are just as investable post Michael is the Chief Financial Officer at RA Capital Management. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Kolchinsky's mom knew her son was gifted - Boston Business Journal His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. The Kolchinskys came to the United States from Russia in 1981, when Peter was 4. Gabe Fox is an Associate with the TechAtlas division of RA Capital Management. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. Sris primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Candice Galvez is an Executive Assistant at RA Capital Management. Bens primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Prior to this role, Tom conducted research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities as a Senior Research Assistant. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital. Kat has a BS in Business Administration, majoring in Accounting from the University of Minnesota, Carlson School of Management. Kathryns primary responsibility at RA is to invest in companies developing solutions that address climate change and environmental sustainability. He is active in both public and private investments In biotechnology areas as diverse as drugs, medical devices, diagnostics, and life science tools. David is Director of Treasury at RA Capital Management. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Peymans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. His doctoral research focused on breast cancer metastasis. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. Brian has a B.S. Craig Randall is Assistant General Counsel at RA Capital Management and Counsel at RA Ventures, RA Capital's incubator for new companies. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. Rebecca Silberman is an Analyst on the Venture Team at RA Capital Management. Prior to Tamarack, Brian held roles as Associate Portfolio Manager and Research Analyst, Healthcare, at Sonar Capital Management. from Harvard College and an M.B.A. from Harvard Business School. Peter Kolchinsky was born in the United States of America. PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Lorena's primary responsibility is to oversee all accounting related activities for the firm. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Peter Pan has long been a character that audiences have held up a critical lens to, as the premise of an eternal boy who recruits isolated children naturally brings up some questions the more a person thinks about it. Prior to Acceleron, Habib held various leadership roles at Bayer AG during his ~22-year tenure with the company. Erins primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. Ross primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Her graduate research investigated novel epigenetic regulators in glioblastoma. Elena Forchielli is an Associate within the Planetary Health division of RA Capital Management. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Becca has a BA in Biology from Colgate University and a PhD in Biology from MIT. Cameron has a BA in Neurobiology from Harvard University. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. Semper Maior: Time to Reboot Biotech RApport Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. This website is for informational purposes only and does not constitute an offer to provide investment advisory or other services by RA Capital Management, L.P. (RA Capital). Michael Varnum is a Research Assistant at RA Capital Management. Special Projects Operations Manager/Chief of Staff. He earned his MS in Bioinformatics from Boston University. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies.